Inventor · disambiguated record
Thomas Jensen
Also filed as: JENSEN THOMAS · JENSEN THOMAS JON
12 granted patents·5 pending applications·34 citations·filing 2013–2024
88Inventor score
Top patents by PatentIndex Score
17 records- 0195US11111290B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Sep 7, 2021·6 cites·9 claims
- 0292US10647762B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted May 12, 2020·5 cites·3 claims
- 0390US11780851B2LRRK2 inhibitorsH LUNDBECK AS·Filed 2022·Granted Oct 10, 2023·2 cites·19 claims
- 0490US9353084B22-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's diseaseLUNDBECK & CO AS H·Filed 2015·Granted May 31, 2016·9 cites·22 claims
- 0589US10487142B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Nov 26, 2019·5 cites·3 claims
- 0688US10472415B2Antibodies specific for hyperphosphorylated tau and methods of useH LUNDBECK AS·Filed 2017·Granted Nov 12, 2019·5 cites·3 claims
- 0788US2025257124A1Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2024·Application pending·0 cites
- 0878US12129289B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2021·Granted Oct 29, 2024·0 cites·15 claims
- 0976US11958865B1Leucine-rich repeat kinase 2 (LRRK2) inhibitorsH LUNDBECK AS·Filed 2023·Granted Apr 16, 2024·0 cites·19 claims
- 1074US11993612B2LRRK2 inhibitorsH LUNDBECK AS·Filed 2023·Granted May 28, 2024·0 cites·19 claims
- 1170US10004738B2Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridinesH LUNDBECK AS·Filed 2016·Granted Jun 26, 2018·1 cites·22 claims
- 1264US9642849B2Nalmefene for reduction of alcohol consumption in specific target populationsH LUNDBECK AS·Filed 2016·Granted May 9, 2017·1 cites·35 claims
- 1363US2024343741A1Leucine-rich repeat kinase 2 (lrrk2) inhibitorsH LUNDBECK AS·Filed 2024·Application pending·0 cites
- 1450US10034874B2Nalmefene for reduction of alcohol consumption in specific target populationsH LUNDBECK AS·Filed 2017·Granted Jul 31, 2018·0 cites·28 claims
- 1549US2014005216A1Nalmefene for reduction of alcohol consumption in specific target populationsLUNDBECK & CO AS H·Filed 2013·Application pending·0 cites
- 1648US2014005217A1Nalmefene for reduction of alcohol consumption in specific target populationsLUNDBECK & CO AS H·Filed 2013·Application pending·0 cites
- 1741US2017066741A12-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's DiseaseH LUNDBECK AS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas Jensen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →